Merck & Co., Inc. (NYSE:MRK) Stock Holdings Increased by Pallas Capital Advisors LLC

Pallas Capital Advisors LLC increased its position in Merck & Co., Inc. (NYSE:MRKFree Report) by 3.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 62,376 shares of the company’s stock after buying an additional 2,270 shares during the period. Pallas Capital Advisors LLC’s holdings in Merck & Co., Inc. were worth $6,800,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in MRK. Ruedi Wealth Management Inc. raised its holdings in shares of Merck & Co., Inc. by 180.2% in the third quarter. Ruedi Wealth Management Inc. now owns 311 shares of the company’s stock valued at $32,000 after buying an additional 200 shares during the last quarter. AlphaMark Advisors LLC bought a new position in shares of Merck & Co., Inc. during the 4th quarter valued at about $34,000. Valued Wealth Advisors LLC bought a new position in shares of Merck & Co., Inc. during the 4th quarter valued at about $42,000. TFO Wealth Partners LLC lifted its stake in Merck & Co., Inc. by 108.1% in the 3rd quarter. TFO Wealth Partners LLC now owns 464 shares of the company’s stock valued at $48,000 after acquiring an additional 241 shares in the last quarter. Finally, Ameliora Wealth Management Ltd. bought a new stake in Merck & Co., Inc. in the 3rd quarter valued at approximately $50,000. Institutional investors and hedge funds own 76.07% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on MRK. TheStreet lowered Merck & Co., Inc. from a “b+” rating to a “c+” rating in a report on Monday, March 4th. Truist Financial restated a “buy” rating and set a $142.00 price objective (up from $139.00) on shares of Merck & Co., Inc. in a research report on Thursday, March 28th. Barclays increased their target price on Merck & Co., Inc. from $135.00 to $145.00 and gave the company an “overweight” rating in a research report on Friday, February 2nd. Wells Fargo & Company increased their target price on Merck & Co., Inc. from $130.00 to $135.00 and gave the company an “equal weight” rating in a research report on Wednesday, March 27th. Finally, UBS Group increased their price target on Merck & Co., Inc. from $135.00 to $148.00 and gave the company a “buy” rating in a research note on Friday, February 2nd. One analyst has rated the stock with a sell rating, four have given a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Merck & Co., Inc. currently has an average rating of “Moderate Buy” and an average price target of $129.71.

View Our Latest Stock Analysis on Merck & Co., Inc.

Merck & Co., Inc. Trading Down 0.8 %

Shares of Merck & Co., Inc. stock opened at $130.93 on Tuesday. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.00 and a current ratio of 1.25. Merck & Co., Inc. has a 52 week low of $99.14 and a 52 week high of $133.10. The stock has a 50 day moving average price of $125.24 and a two-hundred day moving average price of $113.04. The stock has a market capitalization of $331.60 billion, a PE ratio of 935.21, a price-to-earnings-growth ratio of 0.52 and a beta of 0.38.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last posted its earnings results on Thursday, February 1st. The company reported $0.03 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.12. Merck & Co., Inc. had a return on equity of 9.33% and a net margin of 0.61%. The company had revenue of $14.63 billion for the quarter, compared to analyst estimates of $14.49 billion. During the same quarter last year, the company earned $1.62 earnings per share. The company’s revenue for the quarter was up 5.8% on a year-over-year basis. As a group, equities analysts anticipate that Merck & Co., Inc. will post 8.59 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, April 5th. Stockholders of record on Friday, March 15th will be issued a $0.77 dividend. The ex-dividend date of this dividend is Thursday, March 14th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 2.35%. Merck & Co., Inc.’s dividend payout ratio is presently 2,200.00%.

Insider Activity

In related news, EVP Steven Mizell sold 50,694 shares of Merck & Co., Inc. stock in a transaction on Friday, February 2nd. The stock was sold at an average price of $126.65, for a total transaction of $6,420,395.10. Following the sale, the executive vice president now directly owns 23,619 shares in the company, valued at $2,991,346.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, EVP Steven Mizell sold 50,694 shares of Merck & Co., Inc. stock in a transaction on Friday, February 2nd. The stock was sold at an average price of $126.65, for a total transaction of $6,420,395.10. Following the sale, the executive vice president now directly owns 23,619 shares in the company, valued at $2,991,346.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Joseph Romanelli sold 1,000 shares of Merck & Co., Inc. stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $124.89, for a total value of $124,890.00. Following the sale, the insider now owns 19,569 shares in the company, valued at $2,443,972.41. The disclosure for this sale can be found here. Corporate insiders own 0.20% of the company’s stock.

Merck & Co., Inc. Company Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Featured Stories

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.